SCHEMBL16409265

SCHEMBL16409265

COC(=O)c1ccc(C2CC(=O)CCN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.43
NR1H3 Q13133 4/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
UCHL1 P09936 1/20 0.40
USP30 Q70CQ3 1/20 0.40
NPC1 O15118 2/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
ATM Q13315 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16409345 0.88 NR1H2 (0.43) NR1H2NR1H3HDAC1HDAC6UCHL1
SCHEMBL16409318 0.85 NR1H2 (0.41) NR1H2NR1H3HDAC1HDAC6UCHL1
SCHEMBL17782321 0.85 NR1H2 (0.41) NR1H2NR1H3HDAC1HDAC6UCHL1
SCHEMBL21625236 0.85 HTT (0.42) NPC1HTTPOLBALDH1A1TSHR
SCHEMBL16401345 0.85 HTT (0.42) NPC1HTTPOLBALDH1A1TSHR
SCHEMBL1653727 0.84 NPC1 (0.52) NR1H2NR1H3HDAC1HDAC6UCHL1
SCHEMBL29331595 0.84 RORC (0.41) NR1H2NR1H3
SCHEMBL29115999 0.84 NR1H2 (0.50) NR1H2NR1H3
SCHEMBL642698 0.84 NR1H2 (0.50) NR1H2NR1H3
SCHEMBL5458875 0.83 NPC1 (0.48) NR1H2NR1H3HDAC1HDAC6UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093663-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2018-10-09 US disclosed
EP-3299365-A1 PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2018-03-28 EP disclosed
EP-3299365-A1 PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2018-03-28 EP disclosed
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2018-01-11 US disclosed
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2018-01-11 US disclosed
EP-3022192-B1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2017-10-11 EP disclosed
EP-3022192-B1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2017-10-11 EP disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
WO-2015009616-A1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, TFPI, TFPI2 NR1H2 3131/4885NR1H3 3484/4885HDAC1 2864/4885
US-10093663-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof CFB, C5, TFPI NR1H2 3597/4885NR1H3 3818/4885HDAC1 2271/4885
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, C5, TFPI NR1H2 3597/4885NR1H3 3818/4885HDAC1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.